Goldman Sachs
CERE

Goldman Sachs’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Goldman Sachs’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,020,921
Closed -$41.7M – 6177
2024
Q2 		$41.7M Buy
1,020,921
+3,945
+0.4% +$164K 0.01% 1290
2024
Q1 		$43M Buy
1,016,976
+484,219
+91% +$20.3M 0.01% 1267
2023
Q4 		$22.6M Buy
532,757
+208,258
+64% +$5.98M ﹤0.01% 1783
2023
Q3 		$7.08M Sell
324,499
-39,205
-11% -$981K ﹤0.01% 2680
2023
Q2 		$11.6M Sell
363,704
-13,353
-4% -$410K ﹤0.01% 2317
2023
Q1 		$9.2M Buy
377,057
+70,107
+23% +$2.06M ﹤0.01% 2500
2022
Q4 		$9.68M Buy
306,950
+61,153
+25% +$1.73M ﹤0.01% 2614
2022
Q3 		$6.95M Buy
245,797
+144,693
+143% +$4.31M ﹤0.01% 2849
2022
Q2 		$2.67M Buy
101,104
+18,839
+23% +$535K ﹤0.01% 3787
2022
Q1 		$2.88M Sell
82,265
-339,423
-80% -$9.91M ﹤0.01% 3910
2021
Q4 		$13.7M Sell
421,688
-88,059
-17% -$3.11M ﹤0.01% 2478
2021
Q3 		$15M Buy
+509,747
New +$14.3M ﹤0.01% 2334
2021
Q2 		– Sell
-190,266
Closed -$2.61M – 6588
2021
Q1 		$2.61M Buy
190,266
+161,957
+572% +$2.37M ﹤0.01% 3727
2020
Q4 		$469K Buy
+28,309
New +$368K ﹤0.01% 4641

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Goldman Sachs's CERE Position: Q3 2024 in Review

Goldman Sachs sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,020,921 shares — an estimated $41.7M sold.

Goldman Sachs first reported a position in CERE in Q4 2020 and held it in 14 quarters. The position peaked at $43M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Goldman Sachs reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 1,020,921 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $41.7M.
  • Goldman Sachs first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Goldman Sachs's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $43M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.